Patents by Inventor Zhongguo Wang

Zhongguo Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PYRROLOPYRROLE COMPOSITIONS AS PYRUVATE KINASE (PKR) ACTIVATORS
    Publication number: 20240083901
    Abstract: The disclosure relates to modulating pyruvate kinase and provides novel chemical compounds useful as activators of PKR, as well as various uses of these compounds. PKR activating compounds are useful in the treatment of diseases and disorders associated with PKR and/or PKM2, such as pyruvate kinase deficiency (PKD), sickle cell disease (SCD), and thalassemia.
    Type: Application
    Filed: March 21, 2023
    Publication date: March 14, 2024
    Inventors: Anna ERICSSON, Neal GREEN, Gary GUSTAFSON, Bingsong HAN, David R. LANCIA, JR., Lorna MITCHELL, David RICHARD, Tatiana SHELEKHIN, Chase C. SMITH, Zhongguo WANG, Xiaozhang ZHENG
  • Target Ligand
    Publication number: 20240067971
    Abstract: The present disclosure relates to the technical field of genetic engineering, in particular to a target ligand. The target ligand provided by the present disclosure forms a siRNA conjugate with a specific small interfering RNA sequence, which targets to an angiopoietin like 3 (ANGPTL3), and reduce the expression quantity of an ANGPTL3 protein by degrading a transcript of an ANGPTL3 gene in a cell. Therefore, the siRNA conjugate formed by the target ligand provided by the present disclosure may be used to prevent and/or treat a dyslipidemia disease.
    Type: Application
    Filed: April 3, 2023
    Publication date: February 29, 2024
    Inventors: Zhaogui Liu, Ping Chen, Jieting Zhang, Rui Wang, Juan Xu, Zhongguo Fu, Hailin Zhang, Pu Chen
  • Activating pyruvate kinase R
    Patent number: 11844787
    Abstract: This disclosure provides compounds and compositions for activating pyruvate kinase R (PKR) and related methods of manufacturing and using these compounds and compositions.
    Type: Grant
    Filed: June 18, 2021
    Date of Patent: December 19, 2023
    Assignee: NOVO NORDISK HEALTH CARE AG
    Inventors: Anna Ericsson, Neal Green, Gary Gustafson, David R. Lancia, Jr., Gary Marshall, Lorna Mitchell, David Richard, Zhongguo Wang
  • TREATING SICKLE CELL DISEASE WITH A PYRUVATE KINASE R ACTIVATING COMPOUND
    Publication number: 20230381151
    Abstract: Compounds that activate pyruvate kinase R can be used for the treatment of sickle cell disease (SCD). Methods and compositions for the treatment of SCD are provided herein, including a therapeutic compound designated as Compound 1.
    Type: Application
    Filed: December 22, 2022
    Publication date: November 30, 2023
    Inventors: Anna ERICSSON, Neal GREEN, Gary GUSTAFSON, Bingsong HAN, David R. Lancia, JR., Lorna MITCHELL, David RICHARD, Tatiana SHELEKHIN, Chase C. SMITH, Zhongguo WANG, Xiaozhang ZHENG
  • NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT
    Publication number: 20230346753
    Abstract: The present invention relates to compounds and compositions for the inhibition of NAMPT, their synthesis, applications and antidotes.
    Type: Application
    Filed: December 2, 2022
    Publication date: November 2, 2023
    Inventors: Kenneth W. Bair, Timm R. Baumeister, Alexandre J. Buckmelter, Karl H. Clodfelter, Peter Dragovich, Francis Gosselin, Bingsong Han, Jian Lin, Dominic J. Reynolds, Bruce Roth, Chase C. Smith, Zhongguo Wang, Po-Wai Yuen, Xiaozhang Zheng
  • Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators
    Patent number: 11649242
    Abstract: The disclosure relates to modulating pyruvate kinase and provides novel chemical compounds useful as activators of PKR, as well as various uses of these compounds. PKR activating compounds are useful in the treatment of diseases and disorders associated with PKR and/or PKM2, such as pyruvate kinase deficiency (PKD), sickle cell disease (SCD), and thalassemia.
    Type: Grant
    Filed: April 23, 2021
    Date of Patent: May 16, 2023
    Assignee: FORMA THERAPEUTICS, INC.
    Inventors: Anna Ericsson, Neal Green, Gary Gustafson, Bingsong Han, David R. Lancia, Jr., Lorna Mitchell, David Richard, Tatiana Shelekhin, Chase C. Smith, Zhongguo Wang, Xiaozhang Zheng
  • PYRIDIN-2(1H)-ONE QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS
    Publication number: 20230125739
    Abstract: The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: where A, U, W1, W2, W3, R1-R6, and R9 are described herein.
    Type: Application
    Filed: November 9, 2022
    Publication date: April 27, 2023
    Applicant: FORMA Therapeutics, Inc.
    Inventors: Jian Lin, Anna Ericsson, Ann-Marie Campbell, Gary Gustafson, Zhongguo Wang, R. Bruce Diebold, Susan Ashwell, David R. Lancia, JR., Justin Andrew Caravella, Wei Lu
  • PIPERIDINE DERIVATIVES AND COMPOSITIONS FOR THE INHIBITION OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT)
    Publication number: 20230110003
    Abstract: The present invention relates to compounds and compositions for the inhibition of NAMPT, their synthesis, applications and antidotes.
    Type: Application
    Filed: September 9, 2022
    Publication date: April 13, 2023
    Inventors: Kenneth W. Bair, Timm R. Baumeister, Alexandre J. Buckmelter, Karl H. Clodfelter, Bingsong Han, Judith D. Kuntz, Jian Lin, Dominic J. Reynolds, Chase C. Smith, Zhongguo Wang, Xiaozhang Zheng
  • Compounds and compositions for the inhibition of NAMPT
    Patent number: 11547701
    Abstract: The present invention relates to compounds and compositions for the inhibition of NAMPT, their synthesis, applications and antidotes.
    Type: Grant
    Filed: September 11, 2020
    Date of Patent: January 10, 2023
    Assignees: Valo Health, Inc., Genentech, Inc.
    Inventors: Kenneth W. Bair, Timm R. Baumeister, Alexandre J. Buckmelter, Karl H. Clodfelter, Peter Dragovich, Francis Gosselin, Bingsong Han, Jian Lin, Dominic J. Reynolds, Bruce Roth, Chase C. Smith, Zhongguo Wang, Po-Wai Yuen, Xiaozhang Zheng
  • Carboxamides as ubiquitin-specific protease inhibitors
    Patent number: 11524966
    Abstract: The present disclosure relates to modulators, such as inhibitors, of at least one pathway chosen from USP28 and USP25, pharmaceutical compositions comprising the inhibitors, and methods of using the inhibitors. The modulators, such as inhibitors, of at least one pathway chosen from USP28 and USP25 can be useful in the treatment of cancers, among other ailments.
    Type: Grant
    Filed: August 9, 2018
    Date of Patent: December 13, 2022
    Assignee: Valo Health, Inc.
    Inventors: David J. Guerin, Pui Yee Ng, Zhongguo Wang, Tatiana Shelekhin, Justin Caravella, Hongbin Li, Stephanos Ioannidis, Mary-Margaret Zablocki
  • ACTIVATING PYRUVATE KINASE R
    Publication number: 20220378756
    Abstract: The compound (S)-1-(5-((2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl)sulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrroll-2(1H)-yl)-3-hydroxy-2-phenylpropan-1-one, or a pharmaceutically acceptable salt thereof, is useful to increase the affinity of hemoglobin for oxygen. Methods and compositions for the treatment of a hemoglobinopathies are provided herein, including certain pharmaceutical compositions for activating PKR.
    Type: Application
    Filed: September 18, 2020
    Publication date: December 1, 2022
    Inventors: Anna Ericsson, Sanjeev Forsyth, Neal Green, Gary Gustafson, Patrick F. Kelly, David R. Lancia, JR., Gary Marshall, Lorna Mitchell, Madhu Mondal, Maria Ribadeneira, David Richard, Patricia Schroeder, Zhongguo Wang
  • Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
    Patent number: 11498913
    Abstract: The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: where A, U, W1, W2, W3, R1-R6, and R9 are described herein.
    Type: Grant
    Filed: November 23, 2020
    Date of Patent: November 15, 2022
    Assignee: FORMA Therapeutics, Inc.
    Inventors: Jian Lin, Anna Ericsson, Ann-Marie Campbell, Gary Gustafson, Zhongguo Wang, R. Bruce Diebold, Susan Ashwell, David R. Lancia, Jr., Justin Andrew Caravella, Wei Lu
  • Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyltransferase (NAMPT)
    Patent number: 11479564
    Abstract: The present invention relates to compounds and compositions for the inhibition of NAMPT, their synthesis, applications and antidotes.
    Type: Grant
    Filed: September 16, 2020
    Date of Patent: October 25, 2022
    Assignee: Valo Health, Inc.
    Inventors: Kenneth W. Bair, Timm R. Baumeister, Alexandre J. Buckmelter, Karl H. Clodfelter, Bingsong Han, Judith D. Kuntz, Jian Lin, Dominic J. Reynolds, Chase C. Smith, Zhongguo Wang, Xiaozhang Zheng
  • INHIBITING FATTY ACID SYNTHASE (FASN)
    Publication number: 20220315565
    Abstract: The present disclosure is directed to inhibitors of FASN. The compounds can be useful in the treatment of disease or disorders associated with the inhibition of FASN. For instance, the disclosure is concerned with compounds and compositions for inhibition of FASN, methods of treating, preventing, or ameliorating diseases or disorders associated with the inhibition of FASN, and methods of synthesis of these compounds.
    Type: Application
    Filed: February 10, 2022
    Publication date: October 6, 2022
    Inventors: Matthew W. Martin, Mary-Margaret Zablocki, Scot Mente, Christopher Dinsmore, Zhongguo Wang, Xiaozhang Zheng
  • ACTIVATING PYRUVATE KINASE R
    Publication number: 20220304987
    Abstract: The compound (S)-1-(5-((2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl)sulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-3-hydroxy-2-phenylpropan-1-one, or a pharmaceutically acceptable salt thereof, is useful to increase the affinity of hemoglobin for oxygen. Methods and compositions for the treatment of a hemoglobinopathies are provided herein, including certain pharmaceutical compositions for activating PKR.
    Type: Application
    Filed: March 18, 2022
    Publication date: September 29, 2022
    Inventors: Anna Ericsson, Neal Green, Gary Gustafson, David R. Lancia, JR., Gary Marshall, Lorna Mitchell, David Richard, Zhongguo Wang, Sanjeev Forsyth, Patrick F. Kelly, Madhu Mondal, Maria Ribadeneira, Patricia Schroeder
  • PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS
    Publication number: 20220281869
    Abstract: The application relates to inhibitors of USP1 useful in the treatment of cancers, and other USP1 associated diseases and disorders, having the Formula: where R1, R2, R3, R3?, R4, R5, X1, X2, X3, X4, and n are described herein.
    Type: Application
    Filed: September 30, 2021
    Publication date: September 8, 2022
    Inventors: Alexandre Joseph Buckmelter, Stephanos Ioannidis, Bruce Follows, Gary Gustafson, Minghua Wang, Justin Andrew Caravella, Zhongguo Wang, Edward L. Fritzen, Jian Lin
  • Thienopyrazine carboxamides as ubiquitin-specific protease inhibitors
    Patent number: 11325917
    Abstract: The disclosure relates to inhibitors of USP28 and/or USP25 useful in the treatment of cancers, inflammation, autoimmune diseases, and infectious diseases, having the Formula: (I), where R1, R2, R3, R4, R4?, R5, R6, X, and n are described herein.
    Type: Grant
    Filed: August 26, 2020
    Date of Patent: May 10, 2022
    Assignee: VALO HEALTH, INC.
    Inventors: David Joseph Guerin, Kenneth W. Bair, Justin A. Caravella, Stephanos Ioannidis, David R. Lancia, Jr., Hongbin Li, Steven Mischke, Pui Yee Ng, David Richard, Shawn E. R. Schiller, Tatiana Shelekhin, Zhongguo Wang
  • Inhibiting fatty acid synthase (FASN)
    Patent number: 11299484
    Abstract: The present disclosure is directed to inhibitors of FASN. The compounds can be useful in the treatment of disease or disorders associated with the inhibition of FASN. For instance, the disclosure is concerned with compounds and compositions for inhibition of FASN, methods of treating, preventing, or ameliorating diseases or disorders associated with the inhibition of FASN, and methods of synthesis of these compounds.
    Type: Grant
    Filed: September 15, 2020
    Date of Patent: April 12, 2022
    Assignee: FORMA Therapeutics, Inc.
    Inventors: Matthew W. Martin, Mary-Margaret Zablocki, Scot Mente, Christopher Dinsmore, Zhongguo Wang, Xiaozhang Zheng
  • ACTIVATING PYRUVATE KINASE R
    Publication number: 20220087983
    Abstract: The compound (S)-1-(5-((2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl)sulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-3-hydroxy-2-phenylpropan-1-one, or a pharmaceutically acceptable salt thereof, is useful to increase the affinity of hemoglobin for oxygen. Methods and compositions for the treatment of a hemoglobinopathies are provided herein, including certain pharmaceutical compositions for activating PKR.
    Type: Application
    Filed: September 17, 2021
    Publication date: March 24, 2022
    Inventors: Anna Ericsson, Neal Green, Gary Gustafson, David R. Lancia, JR., Gary Marshall, Lorna Mitchell, David Richard, Zhongguo Wang, Sanjeev Forsyth, Patrick F. Kelly, Madhu Mondal, Maria Ribadeneira, Patricia Schroeder
  • Compounds and compositions for the inhibition of NAMPT
    Patent number: 11279687
    Abstract: The present invention relates to compounds and compositions for the inhibition of NAMPT, their synthesis, applications and antidotes. An embodiment of the invention is the provision of a compound of Formula IIIA.
    Type: Grant
    Filed: March 20, 2020
    Date of Patent: March 22, 2022
    Assignees: Valo Health, Inc., Genentech, Inc.
    Inventors: Kenneth W. Bair, Timm R. Baumeister, Alexandre J. Buckmelter, Karl H. Clodfelter, Bingsong Han, Jian Lin, Dominic J. Reynolds, Chase C. Smith, Zhongguo Wang, Xiaozhang Zheng, Po-Wai Yuen